Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India approves plans for UNESCO biotech training centre

This article was originally published in Scrip

Executive Summary

India has approved plans to establish UNESCO's (United Nations Educational, Scientific and Cultural Organisation) regional centre for training and education in biotechnology in Faridabad, Haryana. India's cabinet recently approved the proposal, which is being implemented with a budget of Rs995.5 million ($19.8 million). The proposed centre would act as the focal point for co-operation among member countries of the Asian region in biotechnology. It would serve as a regional hub for interdisciplinary education and training in biotechnology with emphasis on novel education programmes relevant to industry, including biotech drug discovery science, nanoscience and medicine, imaging techniques and bioengineering. It is expected to help overcome the shortage of skilled personnel in these areas in India. Collaboration with UNESCO is also expected to open up gateways to international institutions such as the European Molecular Biology Organisation and the International Union of Biochemistry and Molecular Biology, the Indian government added.

You may also be interested in...



Sun Sees New Prescriptions Drought Amid COVID-19

Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.

COVID-19 and What Doctors Expect From Pharma In India

Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.

Sun Flags Up New Prescriptions Drought Amid COVID-19

Sun Pharma says that the first quarter of 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132530

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel